Oncology Medical News about high-sensitive radioimmunoassay;human serum hepcidin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

High-sensitive radioimmunoassay for human serum hepcidin
British Journal of Haematology, 06/08/09

Grebenchtchikov N et al. – Study describes a validated and competitive radioimmunoassay (RIA) for serum hepcidin (hepatic peptide hormone that plays a central role in body iron metabolism). This assay is accurate, shows good reproducibility, has by far the lowest limit of detection (0·02 µg/l) and large numbers of samples can be measured in one run.

Methods

Aim was to develop and validate a high-sensitive hepcidin assays
A RIA to measure hepcidin quantitatively in human serum was developed

Results

This assay exhibited a very low detection limit (0·02 µg/l), low imprecision, and good linearity and recovery
It showed an excellent correlation with previously described quantitative time-of-flight mass spectrometry assay
The RIA detected:
1. Differences in mean hepcidin levels between men (n=29) and women (n=35)
2. Differences between individuals of different HFE-genotypes (n=60) and
3. Daily increases in hepcidin levels (n=64)

The assay is: